Amylyx Pharmaceuticals, Inc. — Director's Dealing 2025

Apr 2, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Amylyx Pharmaceuticals, Inc. (AMLX)
CIK: 0001658551
Period of Report: 2025-03-31

Reporting Person: Mazzariello Gina (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-31	Common Stock	S	9192	$3.4763	Disposed	187969	Direct

Footnotes

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.